Company Overview and News
Investors interested in stocks from the Electronics - Semiconductors sector have probably already heard of Cirrus Logic (CRUS - Free Report) and Pixelworks (PXLW - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
CY CRUS PXLW
(Reuters) - Apple Inc’s older iPhones would no longer include lightning-to-headphone jack adapters, the company’s website showed on Thursday, which according to Barclays would hurt audio chip supplier Cirrus Logic.
Cirrus Logic Inc. CRUS, -4.51% shares are down 4% in Thursday afternoon after Barclays analyst Blayne Curtis commented on Apple Inc.'s AAPL, +1.91% decision to stop providing headphone dongles to those who buy new iPhones. Previously, when consumers bought an iPhone that lacked a headphone jack, they would receive a dongle in the box that would allow them to adapt their traditional headphones for connectivity with a Lightning port.
Synaptics Incorporated (SYNA - Free Report) recently announced that it is sampling its ClearView R63455 display driver IC (DDIC), comprising the industry’s first “dual-display 2K resolution combined with unique foveal transport support for next generation virtual reality head-mounted displays (HMDs).” Additionally, the company’s VXR7200 VR Bridge solution equips devices with “high-speed DisplayPort connectivity supporting full VESA DP1.
SYNA CRUS MSFT AMD URBN
Investors looking for stocks in the Electronics - Semiconductors sector might want to consider either Cirrus Logic (CRUS - Free Report) or Pixelworks (PXLW - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
CRUS PXLW URBN
Alibaba Group Holding Limited (BABA - Free Report) reported first-quarter fiscal 2019 earnings of $1.22 per share, missing the Zacks Consensus Estimate by 7 cents. However, earnings increased 5% year over year.
RMBS BABA IFNNY YOKU VEEV CRUS IFNNF
Texas Instruments (TXN - Free Report) plans to consider North Richardson manufacturing facility to increase its manufacturing capacity, in an attempt to leverage benefits from the growing demand for the company’s products.
RMBS TXN IFNNY CRUS IFNNF
Smartphone shipments are expected to be healthy in Q3 and Q4, with an iPhone production ramp still on track for the latter half of the year. We believe the slightly late iPhone LCD model production ramp could lead to positive sentiment surrounding iPhone sales in late September. Our work also suggests Chinese OEMs will increase their orders in Q4 in order to achieve 2018 shipment targets.
AAPL CRUS AUO
Analog Devices Inc. (ADI - Free Report) reported third-quarter fiscal 2018 adjusted earnings of $1.53 per share, beating the Zacks Consensus Estimate of $1.46. Moreover, the bottom line increased 22% year over year and 6% sequentially. Also, the figure surpassed the guided range of $1.38-$1.52.
RMBS IFNNY CRUS ADI IFNNF
Alibaba Group Holding Limited’s (BABA - Free Report) expanding core commerce and cloud portfolio are expected to have performed well, which is likely to be reflected when the company reports fiscal first-quarter 2018results on Aug 23.
RMBS BABA IFNNY CRUS IFNNF
SECURITIES AND EXCHANGE COMMISSION
(Aug 15): Smartphone suppliers were among the worst-performing semiconductor stocks Tuesday after two disappointing earnings reports from peers in Asia alarmed investors.
CRUS NVDA MCHP SWKS AMAT AAPL AVGO ADI MS BRCM
Synaptics Incorporated (SYNA - Free Report) delivered fourth-quarter fiscal 2018 non-GAAP earnings of $1 per share that beat the Zacks Consensus Estimate of 92 cents. The figure also came in line with the upper end of the guided range of 80 cents to $1 per share. However, the figure declined 15.3% from the year-ago quarter. Revenues declined approximately 8.9% from the year-ago quarter to $388.5 million and were within the guidance range of $370-$410 million.
GJV SYNA NWS NWSA CRUS MSFT AMD
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET